Emcure slashes prices of weight management drug Poviztra by up to 55%

New Delhi, Emcure Pharmaceuticals on Thursday announced a reduction in the price of its weight management drug, Poviztra, a semaglutide injection, by up to 55 per cent to expand patient access.

The starting dose of Poviztra (0.25 mg) will now be available at Rs 3,999 per month (inclusive of taxes), a reduction of 55 per cent from the previous price of Rs 8,790, with the price reduction effective from April 3, 2026.

Across all doses, the price of Poviztra has been reduced by an average of 47 per cent. The drug is offered in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg.


Poviztra is the second brand of Novo Nordisk's semaglutide injection for obesity and will be exclusively distributed and commercialised by Emcure Pharma in India.

Novo Nordisk India on Tuesday announced price reductions for Ozempic and Wegovy in India, days after the launch of generic versions of semaglutide injections for patients living with type 2 diabetes and obesity.

Indian pharma majors recently announced the launch of their generic versions following the molecule behind products like Ozempic and Wegovy, going off patent in India.

"As the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy at the revised price.

"The price revision, effective April 3, 2026, will bring the innovator molecule, backed by robust clinical and real-world evidence, within the reach of a significantly larger patient base across the country - at a time when obesity and weight-related health conditions are emerging as one of India's most pressing public health challenges," Emcure Pharmaceuticals said in a statement.

Satish Mehta, CEO and Managing Director of Emcure Pharma, emphasized that this price revision is a vital step towards addressing the obesity epidemic in India, with nearly 254 million people living with generalized obesity.

"The reduced pricing will support Emcure's ongoing commitment to improving health outcomes and increasing access to scientifically validated weight-management therapies," he added.